The GLP-1 Cost Index: What GLP-1s Actually Cost in 2026
A maintained, dated reference for GLP-1 pricing — insurance copays, brand list price, manufacturer cash-pay programs, compounded telehealth, and flat-price options — for semaglutide and tirzepatide.
About this index
A maintained reference for what GLP-1 medicines actually cost in the United States. Prices verified October 5, 2026 and change often — treat these as typical figures, not a quote. This is educational information, not medical or financial advice. Compounded semaglutide and tirzepatide are prepared by licensed 503A and 503B compounding pharmacies.
There is no single price for a GLP-1. The exact same molecule can cost you $0, $139, $349, or over $1,000 a month depending on how you pay for it. This page lays out every path side by side, updated with current 2026 figures, so you can compare like with like.
Semaglutide: monthly cost by payment path (2026)
| How you pay | Monthly cost (2026) | Notes |
|---|---|---|
| Insurance copay (if covered) | $0–$150 | Frequently not covered for weight loss; prior authorization is common. |
| Brand list price (no insurance) | ≈$1,350 | The sticker/WAC price. Almost nobody pays this out of pocket. |
| Manufacturer cash-pay (NovoCare, Wegovy®) | $199 intro → $349 | $199 for the two starter doses through Dec 31, 2026, then $349/mo for the maintenance pen. No insurance billed. |
| Compounded via telehealth | $200–$500 | Since the 2025 shortage delisting, limited to patient-specific 503A preparations with a documented clinical reason. |
| LunaRx (flat, compounded) | $139 flat | Same price at every dose; $0 if a clinician does not approve you. |
Tirzepatide: monthly cost by payment path (2026)
| How you pay | Monthly cost (2026) | Notes |
|---|---|---|
| Insurance copay (if covered) | $0–$150 | Frequently not covered for weight loss; prior authorization is common. |
| Brand list price (no insurance) | ≈$1,060 | The sticker/WAC price. Almost nobody pays this out of pocket. |
| Manufacturer cash-pay (LillyDirect vials, Zepbound®) | $299–$449 | By dose: $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg, refilled within 45 days). Self-pay only. |
| Compounded via telehealth | $200–$500 | Since the 2025 shortage delisting, limited to patient-specific 503A preparations with a documented clinical reason. |
| LunaRx (flat, compounded) | $149 flat | Same price at every dose; $0 if a clinician does not approve you. |
Why the same drug has so many different prices
The list price is what the manufacturer sets; it is rarely what anyone pays. Insurance can knock it down to a small copay — but many plans exclude GLP-1s for weight loss entirely, which is why so many people pay cash. Manufacturer cash-pay programs (NovoCare for Wegovy, LillyDirect for Zepbound) sell the brand drug directly at a fraction of list. Compounded versions, prepared by licensed 503A/503B pharmacies and reached through telehealth, are a separate track with their own pricing.
The hidden cost: pricing that steps up with your dose
GLP-1s are titrated — you start low and increase the dose over months. That matters for your budget, because several pricing models rise as your dose rises. The manufacturer cash programs are a clear example: Wegovy's self-pay price goes from a $199 introductory rate to $349 for maintenance, and Zepbound vials climb from $299 to $449 as you titrate up. The low number in the ad is often not the number you pay by month three or four.
Compare the maintenance price, not the intro price
When a program advertises a low starting rate, find the price at the dose you expect to reach and compare that. An introductory or low-dose price that steps up is common; a flat, dose-independent price is not.
What flat, dose-independent pricing means
A flat price stays the same whatever your dose. LunaRx, for example, charges $139/month for semaglutide and $149/month for tirzepatide, the same at every dose, and $0 if a licensed clinician does not approve you — so you can budget from day one instead of bracing for a step-up. Because the price never moves with the dose, there is no penalty for following the titration schedule.
Want this handled for you?
LunaRx — clinician-led GLP-1 care with a plan to come off
LunaRx connects you with a licensed clinician for an online evaluation. Depending on your state that is a live or a store-and-forward visit. If the clinician determines a GLP-1 is appropriate for you, a licensed pharmacy dispenses it — with a plan to come off when you’re ready. The prescribing decision is the clinician’s alone, and approval is not guaranteed.
How to compare GLP-1 prices fairly
- Compare the monthly cost at the dose you expect to reach, not the introductory or lowest-dose price.
- Check whether the price is flat or steps up as you titrate.
- Include shipping and any membership or visit fees in the total.
- Ask whether muscle-preserving support and a come-off plan are included or cost extra.
- Confirm you are only charged if a clinician approves the treatment.
- For brand cash programs, note any refill-timing rules (e.g., Zepbound vials require a 45-day refill to hold the price).
GLP-1 cost — frequently asked questions
- What is the cheapest way to get a GLP-1 in 2026?
- If your insurance covers it for your condition, a copay ($0–$150) is usually cheapest. Without coverage, the lowest predictable options are manufacturer cash-pay programs (Wegovy from $199 intro/$349 maintenance; Zepbound vials $299–$449 by dose) and flat-price telehealth (e.g., LunaRx at $139 semaglutide / $149 tirzepatide). Verify current prices before deciding.
- Why is the brand list price so high if no one pays it?
- The list (WAC) price is a starting point that insurance, rebates, and manufacturer programs discount. It's the number you'd face only with no coverage and no cash program — which is why manufacturers now sell directly at far lower cash prices.
- Does the price go up as my dose increases?
- In several models, yes. Manufacturer cash programs step up as you titrate (Wegovy $199→$349; Zepbound $299→$449). Flat-price programs charge the same at every dose. Always compare the maintenance-dose price.
- How much does compounded semaglutide or tirzepatide cost?
- Through telehealth, compounded versions typically run $200–$500/month. Since the 2025 shortage delisting, compounding is limited to patient-specific 503A preparations with a documented clinical reason. Compounded drugs are prepared by licensed 503A and 503B pharmacies.
- Is compounded the same as the brand drug?
- No. Compounded semaglutide and tirzepatide are not FDA-approved and are not interchangeable with the branded products. They are prepared by licensed 503A/503B pharmacies against a prescription.
Cite this page
The GLP-1 Cost Index, The GLP Journal, 2026. URL: theglpjournal.com/glp-1-cost-index. Figures verified October 5, 2026; brand cash-pay prices from NovoCare (Wegovy) and Eli Lilly/LillyDirect (Zepbound). See the sources listed below.
How we keep this current
Prices are checked against manufacturer and FDA primary sources and re-dated when they change. If you spot a figure that has moved, the sources below are the authoritative references. Nothing here is medical or financial advice.
Sources
Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.
- 1.Wegovy (semaglutide) self-pay pricing — NovoCare Pharmacy
Novo Nordisk (NovoCare) · 2026
Wegovy self-pay via NovoCare: $199/month introductory price for the two starter doses (offer through Dec 31, 2026), then $349/month for the standard maintenance pen. NovoCare does not bill insurance. Verified 2026-09-28.
- 2.Lilly lowers the price of Zepbound (tirzepatide) single-dose vials
Eli Lilly and Company · 2026
Zepbound single-dose vials, self-pay via LillyDirect: $299/month (2.5 mg), $399 (5 mg), and $449 (7.5–15 mg, when refilled within 45 days). Self-pay only; no insurance. Verified 2026-09-28.
- 3.FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
U.S. Food and Drug Administration · 2025
Shortages resolved (tirzepatide December 2024, semaglutide February 2025) and the compounding enforcement deadlines that followed.
- 4.Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A
U.S. Food and Drug Administration, guidance for industry · 2018
A 503A pharmacy may not compound, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available product. Patient-specific compounding remains possible where the prescriber documents a clinically significant difference for that patient.
- 5.FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
U.S. Food and Drug Administration · 2026
April 2026 proposal to exclude these molecules from the 503B bulk drug substances list.
Get the weekly research update
New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.
Unsubscribe anytime. Read our privacy policy.
